From: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
 | All patients | Screened patients | Unscreened patients | P value |
---|---|---|---|---|
 | (N = 18,688) | (N = 3020) | (N = 15668) | |
Characteristic | No. (%)a | No. (%)b | No. (%)b | |
Age, years, mean (SD) | 55.0 (13.5) | 52.5 (15.4) | 55.5 (13.0) | <0.0001 |
Sex | Â | Â | Â | <0.0001 |
 Female | 10,608 (56.8) | 1305 (12.3) | 9303 (87.7) |  |
 Male | 8080 (43.2) | 1715 (21.2) | 6365 (78.8) |  |
Race/ethnicity | Â | Â | Â | <0.0001 |
 White | 13,168 (70.5) | 2168 (16.5) | 11000 (83.5) |  |
 Hispanic | 2319 (12.5) | 402 (17.3) | 1917 (82.7) |  |
 Black | 2092 (11.2) | 247 (11.8) | 1845 (88.2) |  |
 Asian | 508 (2.7) | 76 (15.0) | 432 (85.0) |  |
 Other | 601 (3.2) | 127 (21.1) | 474 (78.9) |  |
US residence | 18,090 (96.8) | 2896 (16.0) | 15194 (84.0) | 0.002 |
HBV risk factorc,d | 5391 (28.8) | 1016 (18.8) | 4375 (81.2) | <0.0001 |
 Birthplace | 1286 (6.9) | 220 (17.1) | 1066 (82.9) |  |
 Abnormal liver function | 368 (2.0) | 170 (46.2) | 198 (53.8) |  |
 Hepatitis (not specified) | 173 (0.9) | 90 (52.0) | 83 (48.0) |  |
 Hepatitis C | 213 (1.1) | 104 (48.8) | 109 (51.2) |  |
 Other liver conditions | 3821 (20.4) | 610 (16.0) | 3211 (84.0) |  |
 HIV | 70 (0.4) | 39 (55.7) | 31 (44.3) |  |
 Drug abuse | 39 (0.2) | 15 (38.5) | 24 (61.5) |  |
 Sexually transmitted disease | 106 (0.6) | 36 (34.0) | 70 (66.0) |  |
History of HBV infectione | 78 (0.4) | 20 (25.6) | 58 (74.4) | 0.02 |
Cancer type | Â | Â | Â | <0.0001 |
 Solid tumorf | 15,031 (80.4) | 581 (3.9) | 14450 (96.1) |  |
 Hematologic malignancy | 3657 (19.6) | 2439 (66.7) | 1218 (33.3) |  |
Chemotherapy type | Â | Â | Â | <0.0001 |
 Rituximab | 1977 (10.6) | 1360 (68.8) | 617 (31.2) |  |
 Non-rituximab | 16,711 (89.4) | 1660 (9.9) | 15051 (90.1) |  |